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IL1-RN is an important anti-inflammatory cytokine that modulate the inflammation response by binding to IL1 receptors, and as a
consequence inhibits the action of proinflammatory cytokines IL1a and IL1b. In this study, we hypothesise that sequence variants in
the IL1-RN gene are associated with prostate cancer risk. The study population, a population-based case–control study in Sweden,
consisted of 1383 prostate cancer case patients and 779 control subjects. We first selected 18 sequence variants covering the IL1-RN
gene and genotyped these single-nucleotide polymorphisms (SNPs) in 96 control subjects. Gene-specific haplotypes of IL1-RN were
constructed and four haplotype-tagging single-nucleotide polymorphisms (htSNPs) were identified (rs878972, rs315934, rs3087263
and rs315951) that could uniquely describe 495% of the haplotypes. All study subjects were genotyped for the four htSNPs. No
significant difference in genotype frequencies between cases and controls were observed for any of the four SNPs based on a
multiplicative genetic model. Overall there was no significant difference in haplotype frequencies between cases and controls;
however, the prevalence of the most common haplotype (ATGC) was significantly higher among cases (38.7%) compared to
controls (33.5%) (haplotype-specific P¼0.009). Evaluation of the prostate cancer risk associated with carrying the ‘ATGC’ haplotype
revealed that homozygous carriers were at significantly increased risk (odds ratio (OR)¼1.6, 95% confidence interval (CI)¼1.2–
2.2), compared to noncarriers, while no significant association was found among subjects heterozygous for the haplotype (OR¼1.0,
95% CI¼0.8–1.2). Restricting analyses to advanced prostate cancer strengthened the association between the ‘ATGC’ haplotype
and disease risk (OR for homozygous carriers vs noncarriers 1.8, 95% CI¼1.3–2.5). In conclusion, the results from this study support
the hypothesis that inflammation has a role of in the development of prostate cancer, but further studies are needed to identify the
causal variants in this region and to elucidate the biological mechanism for this association.
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Chronic inflammatory conditions may increase the incidence
of several malignant diseases, including prostate cancer. This
association is most well established in individuals with inflamma-
tory bowel disease, but the evidence is strong also for cancers of
the bladder, stomach, oesophagus, pancreas and lung (Shacter and
Weitzman, 2002). In 1999, De Marzo et al (1999) suggested that
proliferative inflammatory atrophy may progress to prostatic
intraepithelial neoplasia and prostate cancer. In addition, several
retrospective case–control studies have observed an association
between clinical prostatitis and prostate cancer (Dennis et al,
2002). Finally, a systematic genetic analysis revealed an association
between prostate cancer risk and sequence variants in MIC-1,
TLR-4 and the TLR1-TLR6-TLR10 gene cluster, all genes that are
important in the inflammatory response (Lindmark et al, 2004;
Zheng et al, 2004; Sun et al, 2005).
The interleukin-1 receptor antagonist (IL-1RN) belongs to the
IL-1 family that apart from IL-1RN consists of two agonists IL-1a
and IL-1b, and two different receptors, IL-1R type I and IL-1R type
II. The IL-1RN gene is located on 2q14.2 in close proximity to the
genes coding for IL-1a and IL-1b (Steinkasserer et al, 1992). All
three molecules bind to the same IL-1 receptors. IL-1a and IL-1b
are proinflammatory cytokines. By binding to the receptors, a
cascade of events are initiated leading to recruitment and
activation of macrophages and neutrophils, vascular dilation and
fever, and a potent proinflammatory immune response (Dinarello,
1988). When the anti-inflammatory cytokine, IL-1RN, binds to the
same receptors no signal transduction will be elicited on and
thereby the activity of IL-1 is blocked. The relative levels of IL-1RN
and IL-1 at an inflammatory site will determine whether a
proinflammatory state will be initiated and persist or will be
terminated (McIntyre et al, 1991).
The IL-1 system plays an important role in protection against
many different injuries, ranging from microbial colonisation to
malignant transformation (Witkin et al, 2002). Relatedly, sequence
variants within the IL-1RN gene have been associated with various
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smalignancies and infectious diseases (Clay et al, 1994; Blakemore
et al, 1996; El-Omar et al, 2000; Machado et al, 2001), but the role
of IL-1RN polymorphisms in prostate cancer pathogenesis has not
been examined.
The aim of this study was to test for association of prostate
cancer with sequence variants in the IL-1RN gene in a large
population-based study in Sweden and in that way evaluate
whether polymorphisms in a gene that regulates inflammatory
processes might influence the risk of prostate cancer.
SUBJECTS AND METHODS
Study population
A detailed description of the study sample was presented elsewhere
(Lindmark et al, 2004). Briefly, the participants studied come
from a large-scale, population-based case–control study in
Sweden, CAPS (CAncer Prostate in Sweden). The study population
consisted of 1383 prostate cancer case patients and 779 control
subjects. The case participants were recruited from four of the
six regional cancer registries that cover the entire population of
Sweden. Each of these registries serves one health care region
(Northern, Central, Stockholm, and South Eastern) and altogether
encompasses approximately six million inhabitants (67% of
Sweden’s population). The cases were linked to the National
Prostate Cancer Registry and clinical information such as TNM
(tumour-node-metastasis) stage, Gleason sum, PSA level at the
time of diagnosis, methods of diagnosis and primary treatment
were obtained for 95.3% of the cases. The cases were thereafter
classified as either Localised: T1–2 and N0/NX and M0/MX and
Grade I–II/Gleason sum 2–7, and PSAo100 or Advanced (having
or prone to progressive disease): T3/4 or Nþ or Mþ or Grade III
or Gleason sum 8–10 or PSA4100. For cases with at least one
reported family member with prostate cancer, a more detailed
family history of prostate cancer was obtained through additional
questionnaires and record linkage to Swedish Cancer Registry or
medical records. The families were subsequently classified as
hereditary prostate cancer: Three or more relatives with prostate
cancer (52 cases) or familial prostate cancer: two relatives with
prostate cancer (130 cases).
Control subjects were randomly selected from the continuously
updated Swedish Population Registry, frequency matched accord-
ing to the expected age distribution (within 5 years), geographic
origin of the cases and sex. Mean age (age at diagnosis for case
patients and age at inclusion for control subjects) for the cases and
controls were 66.6 and 67.9 years, respectively.
Written informed consent was obtained from each subject. The
study was approved by the Ethical Committee at the two
participating academic institutions, Karolinska Institutet and
Umea ˚ University.
Genotyping
To test for genetic association, a haplotype tagging single-
nucleotide polymorphism (SNPs) approach in the selection of
sequence variants was used. First, we selected a subset of common
SNPs in the target genomic region of IL-1RN using the criteria of
SNPs with minor allele frequencies X5% at a density of 1 SNP per
kb, with additional attention paid to potentially functional SNPs.
In total, 16 SNPs and two repeats (86bp VNTR and 8bp repeat)
were identified through public databases (NCBI dbSNP and
SNPper) (Table 1). The target genomic region was defined as
2kb of the promoter, all exons, introns, and 30UTR, for IL-1RN this
region is approximately 19kb.
We used three methods for genotyping. First, the 16 identified
SNPs and one repeat were genotyped in 94 control subjects using a
50 nuclease assay with TaqMan MGB probes. The SNP genotyping
assays were designed using the Assay-by-Design service, Applied
Biosystems (Applied Biosystems Inc., Foster City, CA, USA). The
samples were analysed on an ABI 7700 sequence detection system.
The VNTR in intron 2 was genotyped using a temperature
modulated heteroduplex analysis on a denaturing high-perfor-
mance liquid chromatography system. This method was performed
as described elsewhere (Jonsson et al, 2002).
Haplotypes of these SNPs were estimated using a Markov Chain
Monte Carlo approach as implemented in the PHASE software
package (http://www.stats.ox.ac.uk/mathgen/software.html). Haplo-
type tagging SNPs (htSNPs), which captured at least 95% of the
haplotype variation among the 94 controls, were selected using the
htSNP2 computer program (www-gene.cimr.cam.ac.uk/clayton/
software/stata). Four htSNPs were identified and they were
genotyped in all 1383 cases and 779 controls. The htSNPs
(rs878972, rs315934, rs3087263, rs315951) were then genotyped
using the MassARRAY system (SEQUENOM, Inc. Valencia, CA,
USA). The DNA samples were labelled blindly and shipped from
Umea ˚ University, Sweden to the core genotyping laboratory in the
Center for Human Genomics, Wake Forest University. In total, 37
controls from the CEPH foundation (1331-01, 1331-02), 29 blind
repeats were spread among the DNA samples. In addition, every
DNA plate contained two water blanks. A full list of PCR primers
and probes and PCR conditions for all systems is available at the
author’s website (www.wfubmc.edu/genomics).
Statistical analysis
Hardy–Weinberg equilibrium (HWE) tests for each sequence
variant and pairwise linkage disequilibrium (LD) tests for all
sequence variants were performed using a replication method, as
previously described (Weir, 1996). For each test, 10000 permuta-
tions were performed and the Fisher probability test statistic of
each replicate was calculated from the new corresponding multi-
locus table using the Genetic Data Analysis software package.
Associations between genotypes and prostate cancer were
assessed by the score test in conditional logistic regression of a
covariate equal to number of rare alleles (0, 1, 2). Genotype-
specific risks were estimated as odds ratios (ORs) with associated
95% confidence intervals (CI) by conditional logistic regression.
When testing for association and estimating ORs, the conditional
Table 1 SNPs selected for genotyping in 94 CAPS control subjects
SNP name, rs-number
Gene location
a (relative to the
ATG, A¼+1)
IL1RN1129  1129 C/T
rs2234679  12 G/C
rs315919 618 C/A
rs4251984 1631 A/G
rs878972 2118 A/C
rs3213448 3702 G/A
IL1RN4696 4696 G/C
rs315936 5352 C/T
rs4251999 6430  /C
rs315934 8111 G/A
rs392503 8600 T/C
rs3087263 10173 G/A
rs1794068 10908 G/A
rs408392 11863 G/T
VNTRintron2
b 12560 +/ 
rs432014 12985 T/C
rs440286 13874 G/T
rs315951 14992 G/C
aPositions are based on the initiation codon (ATG) from IL-1RN genomic DNA
(U65590).
bVariable number of an 86-bp tandem repeat present in intron2. Number
of copies varies from two to five repeats.
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slogistic regression was stratified by each combination of age
(5-year age groups) and geographical region (two regions, as
described in the Study Population section) to adjust for the
matching conducted in collecting control subjects. Tests for
association between haplotypes and prostate cancer risk were
performed using a score test developed by Schaid et al (2002),
using the HAPLO.STAT program (http://www.mayo.edu/hsr/
Sfunc.html) for the R programming language. This method, based
on the generalised linear model framework, allows adjustment for
possible confounding variables and provides both global tests and
haplotype-specific tests. In these analyses, age and geographic
region were adjusted for through indicator variables representing
each combination of age category (5-year age groups) and
geographical region (northern part of Sweden vs south-eastern
part of Sweden and the area of Stockholm). Haplotypes with
estimated frequencies less than 0.005 were pooled into a single
group. Empirical P-values, based on 10000 simulations, were
computed for the global score test and each of the haplotype-
specific score tests. All reported P-values are two-sided.
RESULTS
Except for the SNP rs315951, which significantly deviated from
HWE in cases (P¼0.04) but not in controls (P¼0.34), the
remaining three SNPs were consistent with HWE (all P40.05).
No indication of genotyping error was observed. Genotype
consistency was 100% among the CEPH control DNA, and results
from duplicated samples were 100% concordant, giving an
estimated error rate of 0%.
No significant difference in genotype frequencies between cases
and controls were observed for any of the four SNPs based on a
multiplicative genetic model (Table 2). Assuming a dominant or
recessive allelic effect on prostate cancer risk did not alter these
findings (data not shown). Stratified analyses based on age (o65
or X65), tumour stage (localised or locally advanced) and family
history (sporadic or familial/hereditary) provided no significant
differences in genotype frequency between cases and controls (data
not shown).
In contrast to comparison of genotypes between cases and
controls, an examination of haplotypes yielded evidence of an
association with prostate cancer risk. Analysis of the four htSNPs
revealed eight major haplotypes, including ATGC, ATGG, CTGC,
ACGG, CTAC, ACGC, CTGG, and CTAG of respective SNP
rs878972, rs315934, rs3087263, and rs315951. The distribution of
these haplotypes was not significantly different between cases and
controls (P¼0.116). However, the prevalence of the most common
haplotype (ATGC) was significantly higher among cases (38.7%)
compared to controls (33.5%) (haplotype-specific P¼0.009)
(Table 3). Furthermore, in the stratified analysis the frequency
of the ‘ATGC’ haplotype was higher in sporadic (39.3%) than
in familial (34.8%) prostate cancer cases. Likewise, cases with
advanced disease had a higher prevalence (40.0%) than patients
with localised disease (37.5%). In addition, we also estimated the
prostate cancer risk associated with the most common haplotype.
A significantly increased risk was found among homozygous
haplotype carriers (OR¼1.6, 95% CI¼1.2–2.2), compared to
noncarriers, while no indication of increased risk was observed
among heterozygous carriers (OR¼1.0, 95% CI¼0.8–1.2).
Restricting analyses to aggressive prostate cancer, the risk
associated with being homozygous haplotype carrier was further
evaluated (OR¼1.8, 95% CI¼1.3–2.5).
DISCUSSION
We tested the hypothesis that sequence variants in the IL-1RN gene
are associated with prostate cancer risk in a large population-based
case–control study in Sweden. In this first study of the possible
role of IL1-RN in prostate cancer aetiology, we found an
association with the most common haplotype in IL1-RN. Our data
are in concordance with the growing evidence that chronic
Table 2 Genotype frequencies of IL-1RN htSNPs in prostate cancer
patients and unaffected control subjects
Genotype frequencies, #
(%)
SNP
(position
a) Genotype
Control
subjects
(n¼780)
Case
subjects
(n¼1383) P-value
b
rs878972
(2118A/C)
AA 378 (51.9) 712 (53.4)
AC 293 (40.2) 537 (40.3)
CC 57 (7.7) 85 (6.4) 0.382
rs315934
(8111G/A)
TT 499 (65.2) 885 (65.8)
TC 227 (29.7) 405 (30.1)
CC 39 (5.1) 54 (4.0) 0.277
rs3087263
(10173G/A)
GG 632 (81.5) 1144 (83.4)
GA 138 (17.8) 218 (15.9)
AA 5 (0.6) 10 (0.7) 0.336
rs315951
(14992G/C)
CC 341 (44.2) 640 (46.8)
GC 335 (43.4) 566 (41.4)
GG 96 (12.4) 162 (11.8) 0.610
aPositions are based on the initiation codon (ATG) from IL-1RN genomic DNA
(U65590).
bArmitage test for trend on allele counts.
Table 3 Estimated haplotype frequencies in controls, patients with sporadic prostate cancer (SPC) and patients with advanced prostate cancer
Haplotype Controls Cases SPC Advanced PC
rs878972 rs315934 rs3087263 rs315951 % % Score
a P
b % Score
a P
b % Score
a P
b
A T G C 33.5 38.7 2.60 0.009 39.3 2.85 0.006 40.0 2.67 0.009
A T G G 17.6 15.5  1.01 0.301 15.0  1.24 0.215 15.0  1.15 0.246
C T G C 17.5 15.3  1.16 0.234 15.2  1.22 0.208 14.1  1.78 0.080
A C G G 14.3 13.6  0.58 0.560 14.0  0.41 0.667 14.9 0.45 0.655
C T A C 8.4 7.7  0.80 0.428 7.9  0.64 0.513 8.4  0.20 0.839
A C G C 5.8 5.4  0.38 0.713 4.9  0.89 0.367 4.8  0.86 0.401
C T G G 1.8 2.7 0.97 0.337 2.9 1.06 0.274 2.4 0.17 0.872
C T A G 0.6 0.7 0.33 0.737 0 0
Overall 0.116 0.052 0.024
aScore test statistics for association between haplotype and prostate cancer risk.
bEmpirical P-values based on 10000 replications.
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cancer.
The analyses of individual haplotypes showed that the most
common haplotype (ATGC) was significantly associated with
prostate cancer risk for patients with prostate cancer, and further
this association appears to be stronger in cases with advanced
disease. The fact that the association was strengthened in cases
with advanced disease is of particular note. Genetic markers
capable of predicting increased risk of aggressive disease
compared with increased risk of any prostate cancer diagnosis
are urgently needed, due to the fact that predicting the outcome of
prostate cancer is at present very difficult.
The observation that the most common haplotype was
associated with prostate cancer risk but none individual htSNPs
is of special interest. This highlights the advantages of studying
all variation in a gene with the use of a haplotype-tagging
approach instead of testing a limited number of single variants.
Two different scenarios can explain this observation. First, the
association can be a result of two or more sequence variants in
the region that individually do not confer a detectably increased
risk for prostate cancer, but when using the haplotype-association
strategy the impact of the combined risk becomes statistically
significant. Second and probably more likely, the ATGC-haplotype
may be in strong LD with a risk conferring sequence variant in
IL1-RN, or in the close vicinity to the gene, while the degree of LD
between this risk conferring sequence variant and each of the four
htSNPs is of a much weaker magnitude.
The IL-1RN gene located on chromosome 2 belongs to the IL-1
gene cluster spanning over a region of 360-kb (Steinkasserer et al,
1992). This cluster of genes contains several pro- and anti-
inflammatory cytokine genes that are expressed in both physio-
logical and pathological conditions and plays a key role in the
inflammatory immune response. The high density of IL-1 genes in
this region, which share similar functional characteristics, raises
the question if an association between a haplotype in IL-1RN and
prostate cancer, in fact is an association between another gene or
genes in the cluster and prostate cancer. Knowledge of the degree
of LD across this region is vital to our understanding of which
combinations of genotypes are important in disease. Several
studies have performed analyses to determine the degree of LD
across this region. Consistently, they all show moderate LD in this
gene cluster which is not strictly correlated with distances between
markers (Cox et al, 1998; Bensen et al, 2003). To fully answer this
question, additional SNPs over this region need to be selected for
genetic studies.
The relative levels of IL-1RN together with IL-1a/b at the site of
inflammation will determine whether a proinflammatory reaction
will be initiated and persist or will be terminated. An imbalance
in pro- and anti-inflammatory cytokines caused by a specific
haplotype combination may prevent the normal self-limiting
nature of an immune response. A sequence variant in the
promoter region of the anti-inflammatory cytokine gene IL-10
resulted in decreased levels of IL-10 in cases affected with prostate
cancer. Further, the decreased level of IL-10 was significant
associated with prostate cancer (McCarron et al, 2002). Moreover,
we recently reported an association between a SNP in the anti-
inflammatory cytokine MIC-1 and prostate cancer (Lindmark et al,
2004). MIC-1 is a member of the transforming growth factor b
superfamily: proteins that play a critical role in the pro- and anti-
inflammatory response to infection (Bootcov et al, 1997).
Our study has several strengths, which make it informative for
studies of the genetic epidemiology of prostate cancer. Firstly, it
is large, with DNA samples being available from over 1380 well
clinically characterised cases of prostate cancer, and 779 control
men known not to have been diagnosed with prostate cancer.
Secondly, the ethnic homogeneity of the Swedish population and
the ascertainment of age and residence matched control subjects
makes us confident that population stratification is not an issue.
Finally, the full clinical spectrum of prostate cancer is well
represented, with over 40% of the cases having advanced disease.
Test for HWE revealed that the genotype frequencies of one
htSNP (rs315951) deviated significantly from expected proportions
among prostate cancer subjects. This departure can result from
genotyping errors, population stratification, selection, or statistical
fluctuations. Considering the high quality in genotyping results
(all replicated samples provided concordant genotypes) and the
ethnic homogeneity of the Swedish population, it seems most
plausible that chance alone is responsible for the observed departure
from HWE. Since the departure from HWE was in the direction of
excessive homozygosity, the error in haplotype estimations (based
on the EM algorithm) is not increased (Fallin and Schork, 2000).
Moreover, all statistical inference on haplotypes was based on
simulated P-values, which are expected to be more robust against
departure from HWE compared to the asymptotic distribution of
the score statistic.
In summary, we found evidence of an association between a
common haplotype in the IL1RN gene and prostate cancer in a
Swedish population. This finding provides additional support
for a role of chronic inflammation in prostate cancer development.
Further studies are needed to replicate our finding in other
populations and to elucidate the biological function of the IL1RN
haplotype in relation to prostate cancer risk.
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